Opiant Pharmaceuticals (OPNT) & Baxalta (BXLT) Critical Comparison

Baxalta (NYSE: BXLT) and Opiant Pharmaceuticals (NASDAQ:OPNT) are both companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, dividends, earnings, risk, profitability, analyst recommendations and institutional ownership.

Analyst Recommendations

How to Become a New Pot Stock Millionaire

This is a breakdown of recent ratings and recommmendations for Baxalta and Opiant Pharmaceuticals, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Baxalta 0 0 0 0 N/A
Opiant Pharmaceuticals 0 0 0 0 N/A

Dividends

Baxalta pays an annual dividend of $0.28 per share and has a dividend yield of 0.6%. Opiant Pharmaceuticals does not pay a dividend. Baxalta has increased its dividend for 2 consecutive years.

Insider and Institutional Ownership

4.2% of Opiant Pharmaceuticals shares are owned by institutional investors. 63.8% of Opiant Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares Baxalta and Opiant Pharmaceuticals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Baxalta 9.37% 14.28% 4.62%
Opiant Pharmaceuticals -384.42% -403.59% -145.89%

Valuation and Earnings

This table compares Baxalta and Opiant Pharmaceuticals’ gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Baxalta N/A N/A N/A N/A N/A
Opiant Pharmaceuticals $18.45 million 2.62 $6.58 million $2.94 7.00

Opiant Pharmaceuticals has higher revenue and earnings than Baxalta.

Summary

Baxalta beats Opiant Pharmaceuticals on 5 of the 8 factors compared between the two stocks.

Baxalta Company Profile

Baxalta Incorporated (Baxalta) is a biopharmaceutical company with a portfolio of differentiated therapies that seek to address medical needs across various disease areas, including hemophilia, immunology and oncology. Baxalta’s categories of products include Hemophilia products, such as Advate, Adynovate, Recombinate, Hemofil M, Immunate, Immunine, Rixubis and Prothromplex Total; Inhibitor Therapies products, including FEIBA and OBIZUR; Immunoglobulin Therapies products, which include GAMMAGARD LIQUID/KIOVIG, HYQVIA, GAMMAGARD S/D and SUBCUVIA; BioTherapeutics products, including FLEXBUMIN, BUMINATE, ARALAST NP, GLASSIA NP and CEPROTIN, and Oncology product, such as ONCASPAR. Baxalta Company develops, manufactures and markets a portfolio of treatments for hemophilia and other bleeding disorders, immune deficiencies, alpha-1 antitrypsin deficiency, burns and shock, and other chronic and acute medical conditions, as well as oncology treatments for acute lymphoblastic leukemia.

Opiant Pharmaceuticals Company Profile

Opiant Pharmaceuticals, Inc., a specialty pharmaceutical company, develops pharmacological treatments for substance use, addictive and eating disorders. The company offers NARCAN nasal spray, a treatment to reverse opioid overdoses. Its pipeline of product candidates includes treatments for eating disorders, including bulimia nervosa and binge eating disorders, alcohol use disorders, a long term treatment to prevent relapse for patients with opioid use disorders, cocaine use disorders, and a heroin vaccine. Opiant Pharmaceuticals, Inc. has a collaboration agreement with Titan Pharmaceuticals, Inc. to explore development of a novel approach to the prevention of opioid relapse and overdose in individuals with opioid use disorder. The company was formerly known as Lightlake Therapeutics Inc. and changed its name to Opiant Pharmaceuticals, Inc. in January 2016. Opiant Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Santa Monica, California. Opiant Pharmaceuticals, Inc. is a subsidiary of Pelikin Group.

Receive News & Ratings for Baxalta Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Baxalta and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply